arXiv:2510.24161v1 Announce Type: new Abstract: Multimodal large language models (MLLMs) have advanced vision-language reasoning and are increasingly deployed in embodied agents. However, significant limitations remain: MLLMs generalize poorly across digital-physical spaces and embodiments; vision-language-action models (VLAs) produce low-level actions yet lack robust high-level embodied reasoning; and most embodied large language models (ELLMs) are constrained to digital-space with poor generalization to the physical world. Thus, unified models that operate seamlessly across digital and physical spaces while generalizing across embodiments and tasks remain absent. We introduce the \textbf{Boundless Large Model (BLM$_1$)}, a multimodal spatial foundation model that preserves instruction following and reasoning, incorporates embodied knowledge, and supports robust cross-embodiment control. BLM$_1$ integrates three key capabilities -- \textit{cross-space transfer, cross-task learning, and cross-embodiment generalization} -- via a two-stage training paradigm. Stage I injects embodied knowledge into the MLLM through curated digital corpora while maintaining language competence. Stage II trains a policy module through an intent-bridging interface that extracts high-level semantics from the MLLM to guide control, without fine-tuning the MLLM backbone. This process is supported by a self-collected cross-embodiment demonstration suite spanning four robot embodiments and six progressively challenging tasks. Evaluations across digital and physical benchmarks show that a single BLM$_1$ instance outperforms four model families -- MLLMs, ELLMs, VLAs, and GMLMs -- achieving $\sim\!\textbf{6%}$ gains in digital tasks and $\sim\!\textbf{3%}$ in physical tasks.

arXiv:2510.20727v1 Announce Type: cross Abstract: Objective: Fluoropyrimidines are widely prescribed for colorectal and breast cancers, but are associated with toxicities such as hand-foot syndrome and cardiotoxicity. Since toxicity documentation is often embedded in clinical notes, we aimed to develop and evaluate natural language processing (NLP) methods to extract treatment and toxicity information. Materials and Methods: We constructed a gold-standard dataset of 236 clinical notes from 204,165 adult oncology patients. Domain experts annotated categories related to treatment regimens and toxicities. We developed rule-based, machine learning-based (Random Forest, Support Vector Machine [SVM], Logistic Regression [LR]), deep learning-based (BERT, ClinicalBERT), and large language models (LLM)-based NLP approaches (zero-shot and error-analysis prompting). Models used an 80:20 train-test split. Results: Sufficient data existed to train and evaluate 5 annotated categories. Error-analysis prompting achieved optimal precision, recall, and F1 scores (F1=1.000) for treatment and toxicities extraction, whereas zero-shot prompting reached F1=1.000 for treatment and F1=0.876 for toxicities extraction.LR and SVM ranked second for toxicities (F1=0.937). Deep learning underperformed, with BERT (F1=0.873 treatment; F1= 0.839 toxicities) and ClinicalBERT (F1=0.873 treatment; F1 = 0.886 toxicities). Rule-based methods served as our baseline with F1 scores of 0.857 in treatment and 0.858 in toxicities. Discussion: LMM-based approaches outperformed all others, followed by machine learning methods. Machine and deep learning approaches were limited by small training data and showed limited generalizability, particularly for rare categories. Conclusion: LLM-based NLP most effectively extracted fluoropyrimidine treatment and toxicity information from clinical notes, and has strong potential to support oncology research and pharmacovigilance.